Clinical Management of Heart Conditions

Introduction to Heart Failure

• Heart failure with preserved ejection fraction (HFpEF) is characterized by delayed relaxation of the left ventricle, impaired left ventricular filling, increased myocardial stiffness, increased fibrosis of the myocardium, and myocardial scarring or infiltrative processes, leading to elevated diastolic filling pressures and symptoms of heart failure despite preserved ejection fraction, as noted by the American Heart Association 1
• Advanced age, female gender, hypertension, left ventricular hypertrophy, coronary artery disease, diabetes mellitus, and obesity are primary risk factors for diastolic dysfunction, according to the American College of Cardiology 1

Diagnosis and Assessment

• Diagnosis of HFpEF requires the presence of signs or symptoms of heart failure, normal or slightly reduced systolic function (ejection fraction > 50%), and elevated diastolic filling pressures, based on understanding from 2
• The European Society of Cardiology recommends scheduling clinical follow-up every 6 months and performing echocardiography annually to assess left ventricular size and function, progression of diastolic dysfunction, and development of pulmonary hypertension 3

Pharmacological Therapy

• The American College of Cardiology recommends control of systolic and diastolic hypertension as a Class I recommendation with a Level of Evidence: A 4
• The American College of Cardiology and European cardiology societies support the use of ACE inhibitors/ARBs to improve relaxation and cardiac distensibility, and promote regression of hypertrophy, although large trials like I-PRESERVE and CHARM-Preserved failed to show improved mortality despite physiological improvements, with a strength of evidence level of I 5, 6
• Beta-blockers are particularly beneficial when tachycardia is present, lowering heart rate and increasing diastolic filling period, with an evidence level of I, as recommended by the American College of Cardiology and the European Society of Cardiology 5, 6
• Diuretics should be used cautiously with low initial doses, and are helpful for fluid overload but should avoid excessive preload reduction, with an evidence level of IIa, as suggested by the European Society of Cardiology 5, 6
• Calcium Channel Blockers, such as Verapamil-type agents, may improve relaxation, particularly useful in hypertrophic cardiomyopathy, with an evidence level of IIb, as recommended by the American Heart Association and the European Society of Cardiology 5, 6
• Aldosterone Antagonists, such as low-dose spironolactone (12.5-25 mg daily), should be considered in patients with severe diastolic dysfunction, with an evidence level of IIa, as suggested by the European Society of Cardiology and the American College of Cardiology 5, 4, 6

Lifestyle Modifications

• Moderate sodium restriction, especially in advanced heart failure, daily weight measurements to monitor fluid status, and regular aerobic exercise (except during acute decompensation) are recommended by the American College of Cardiology and European cardiology societies, with a strength of evidence level of IIa 5, 4
• Regular aerobic exercise should be encouraged, except during periods of acute decompensation, and avoiding heavy labor or exhaustive sports, according to the American College of Cardiology, with a strength of evidence level of IIa 4
• Moderate alcohol intake is allowed, except in alcoholic cardiomyopathy where it's prohibited, according to the American College of Cardiology 7

Blood Pressure Management

• The European Society of Cardiology recommends targeting blood pressure < 140/90 mmHg for most patients, and < 130/80 mmHg in patients with diabetes or chronic kidney disease, with a strength of evidence level of I 8
• Individualized systolic BP targets should be set to 130 mmHg and, if well tolerated, <130 mmHg, but not <120 mmHg, as suggested by the European Society of Cardiology, with a strength of evidence level of IIa 8
• The American College of Cardiology recommends a blood pressure target of <140/90 mmHg for most patients, and <150/90 mmHg for patients over 60 years old, with a strength of evidence level of IIb 9

Prognosis and Treatment Considerations

• The prognosis of diastolic heart failure is generally better than systolic heart failure, with lower annual mortality rates (8% vs. 19%), but morbidity remains substantial, as noted by both American and European cardiology societies 5
• Pure diastolic dysfunction may be rare, often occurring with some degree of systolic dysfunction, which can impact treatment recommendations, as noted by the American College of Cardiology 4
• Treatment recommendations for diastolic dysfunction are largely based on therapeutic principles rather than definitive evidence, due to limited data from controlled trials, as agreed upon by the American College of Cardiology and the European Society of Cardiology 6, 4
• Coronary revascularization is recommended in patients with coronary artery disease when ischemia negatively affects diastolic function (Class IIa recommendation), particularly when symptomatic or demonstrable myocardial ischemia is present, or ischemia is judged to have an adverse effect on diastolic function, as recommended by the American College of Cardiology, with a strength of evidence level of IIa 4

Follow-up and Monitoring

• Regular evaluation of symptoms and treatment efficacy, monitoring of medication side effects, assessment of volume status to guide diuretic therapy, and surveillance for progression to systolic dysfunction are essential in managing HFpEF, as recommended by the European Society of Cardiology and the American College of Cardiology, with a strength of evidence level of I 4, 5, 7
• Regular follow-up is essential to assess symptom improvement, monitor for medication side effects, adjust therapy as needed, and evaluate for progression to systolic dysfunction, according to the American College of Cardiology, with a strength of evidence level of IIa 7